Timothy M Mitchell
KALAMAZOO, Michigan – CeeTox, the Kalamazoo-based leader for in vitro toxicology testing, has named Timothy M. Mitchell President. Mr. Mitchell previously held sales, marketing and general management roles for companies including Covance Inc, DCL Medical Laboratories, ACM Medical Laboratories, and Corning Inc.
CeeTox founder and first President, James McKim Ph.D. D.A.B.T., continues in his role as Chief Science Officer and leads CeeTox’s effort to develop and commercialize new in vitro technologies.
“I am excited to join CeeTox as we move into a new phase of growth,” said Mr. Mitchell. “We have helped many pharmaceutical and biotech companies screen new drug candidates and identify those with the lowest risk for toxicity and the highest probability of success. Our latest offerings bring robust decision making and cost-saving in vitro assays to the cosmetic, chemical, and personal care markets as well. This new line of dermal, ocular, and airway assays will help identify potential toxicity in both individual components and final formulations and will allow these companies to comply with their regulatory requirements.”
Using a robust, systems-biology approach, CeeTox originated in vitro models that help identify new drug candidates, chemicals, cosmetics, and consumer products with the lowest risk for toxicity and the highest probability of success. With screens to assess corrosion, irritation, sensitization, and to characterize toxicity in drugs and chemicals, CeeTox supports manufacturers in the pharmaceutical, chemical, and cosmetic industries and helps bring safer products to market faster.
For more information, contact Lorraine Alden, Marketing Coordinator for CeeTox, at +1-269-353-5536 or lalden@ceetox.com
Photo:
http://www.prlog.org/
